E-2101

• Description:

  E-2101 is a novel antispastic agent. E-2101 is a competitive CYP2C19 and CYP2D6 inhibitor with Ki values of 15 and 48 μM, respectively. E-2101 is metabolized by Cytochromes P450 to form monohydroxylated (M1 and M2), dihydroxylated (M3), and N-dealkylated metabolites (M4) . E-2101 can be used in the research of skeletal muscle spasm[1].

• UNSPSC:

  12352005

• Target:

  Cytochrome P450

• Related Pathways:

  Metabolic Enzyme/Protease

• Field of Research:

  Others

• Smiles:

  O=C(NC)CC1=CC2=C(C=C1)C=CN2C3CCN(CCC4=CC=CC=C4F)CC3

• Molecular Formula:

  C24H28FN3O

• Molecular Weight:

  393.50

• References & Citations:

  [1]Zhang ZY, et al. In vitro interactions between a potential muscle relaxant E2101 and human cytochromes P450. Drug Metab Dispos. 2002 Jul;30 (7) :805-13. |[2]Kushida, et al. Solid state characterization of E2101, a novel antispastic drug. J Pharm Sci. 2002 Oct;91 (10) :2193-202.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 1

• Isoform:

  CYP2

• CAS Number:

  [265667-22-9]